Table 4.

Impact of antihypertensive use and systemic atherosclerosis on the association between blood pressure and IPH (n=174^*)

Blood pressure parameters, per 10 mmHg ↑	Model 4: model 3 + Antihypertensive use		Model 5: model 3 + Clinically established ASCVD in other vascular beds		Model 6: model 3 + ankle- brachial index<0.90		Model 7: model 3 + extent of atherosclerosis on MRI
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Systolic blood pressure	0.88 (0.65–1.2)	0.41	0.93 (0.69–1.2)	0.61	0.95 (0.70–1.3)	0.74	0.97 (0.73–1.3)	0.83
Diastolic blood pressure	0.47 (0.29–0.77)	0.003	0.51 (0.29–0.88)	0.017	0.52 (0.30–0.89)	0.018	0.54 (0.32–0.90)	0.018
Pulse pressure	1.2 (0.77–1.8)	0.48	1.2 (0.86–1.7)	0.26	1.3 (0.88–1.9)	0.19	1.3 (0.91–1.8)	0.15

Model 3 adjusted the association between blood pressure and IPH for age, sex, mean wall thickness and plaque length (See Table 3). The association between blood pressure and IPH was further adjusted for antihypertensive use (Model 4) and all available markers for the extent of atherosclerosis (Model 5–7). ASCVD indicates atherosclerotic cardiovascular disease; CI, confidence interval; OR, odds ratio; SD, standard deviation.

^*Two plaques were excluded due to missing blood pressure values.